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Abstract
Background: The chlamydial proteins CT443 (OmcB) and CT521 (rl16) have previously been identified as human B and/or T
cell targets during a chlamydial infection in humans. Here we compare the protective effector mechanism promoted by a
fusion protein composed of CT521 and CT443 (CTH1) with a primary intranasal Chlamydia muridarum infection known to
provide high levels of protection against a genital chlamydial challenge.
Methodology/Principal Findings: The fusion protein CTH1, adjuvanted with a strong Th1 inducing cationic adjuvant
(CAF01), significantly reduced the bacterial shedding compared to a control group in both a C. trachomatis Serovar D and C.
muridarum challenge model. The CTH1/CAF01 vaccine was found to induce polyfunctional T cells consisting of TNFa/IL-2
and TNFa/IL-2/IFN-c positive cells and high titers of CTH1 specific IgG2a and IgG1. By depletion experiments the protection
in the C. muridarum challenge model was demonstrated to be mediated solely by CD4
+ T cells. In comparison, an intranasal
infection with C. muridarum induced a T cell response that consisted predominantly of TNFa/IFN-c co-expressing effector
CD4
+ T cells and an antibody response consisting of C. muridarum specific IgG1, IgG2a but also IgA. This response was
associated with a high level of protection against challenge—a protection that was only partially dependent on CD4
+ T cells.
Furthermore, whereas the antibody response induced by intranasal infection was strongly reactive against the native
antigens displayed in the chlamydial elementary body, only low levels of antibodies against this preparation were found
after CTH1/CAF01 immunization.
Conclusions/Significance: Our data demonstrate that CTH1 vaccination promotes a CD4
+ T cell dependent protective
response but compared with intranasal C. muridarum infection lacks a CD4 independent protective mechanism for
complete protection.
Citation: Olsen AW, Theisen M, Christensen D, Follmann F, Andersen P (2010) Protection against Chlamydia Promoted by a Subunit Vaccine (CTH1) Compared
with a Primary Intranasal Infection in a Mouse Genital Challenge Model. PLoS ONE 5(5): e10768. doi:10.1371/journal.pone.0010768
Editor: Joy Sturtevant, Louisiana State University, United States of America
Received November 30, 2009; Accepted April 23, 2010; Published May 21, 2010
Copyright:  2010 Olsen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was funded by Statens Serum Institut. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: aol@ssi.dk (AWO); pa@ssi.dk (PA)
¤ Current address: Department of Clinical Biochemistry & Immunology, Statens Serum Institut, Copenhagen, Denmark
Introduction
Despite the existence of effective antimicrobial therapy,
Chlamydia trachomatis (Ct) continues to be the leading sexually
transmitted bacteria worldwide, causing an estimated 92 million
new cases annually [1]. Over 225,000 cases were recorded in 2006
in Europe, making it the most frequently reported infectious
disease on the continent [2]. If left untreated, approximately 20%
of women with a chlamydial lower genital tract infection will
develop pelvic inflammatory disease, 4% will develop chronic
pelvic pain, 3% infertility and 2% adverse pregnancy outcomes
[3]. Furthermore it has been suggested that Ct is a major cofactor
for HIV transmission [4] and in the development of cervical
neoplasia [5,6].
Early vaccine trials in humans and non-human primates showed
that it was possible to induce protection against Ct infection with
vaccines based on whole organisms [7,8]. Nonetheless, as the
protection was short lived, and in some trials associated with
immunopathology, the approach was abandoned [9]. Thus,
identification of potential vaccine antigens and exclusion of
potential immunopathogenic components is today an active area
of research, one which has been accelerated by the availability of
the complete Ct serovar D genome sequence [10]. However, so far
only relatively few candidates have proven successful in animal
models (reviewed in [11]).
Rational vaccine design is based on detailed understanding of
pathogen biology and the mechanism leading to protection.
Immunity against intracellular pathogens like Ct is generally
thought to depend on the cellular arm of the immune system. In
agreement with this hypothesis, studies in mice and humans have
highlighted the importance of CD4
+ T-helper type 1 (Th-1) cells in
the clearance of a chlamydial infection [4,12,13]. A number of
reports dealing with various pathogens in different animal models
have indicated that not only the magnitude but also the quality of
the T cell response appears to have significant impact on the
establishment of protective memory and protection [14–18].
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an important role during a secondary encounter with Ct [19–21].
Their role and the exact mechanism of action are however still not
clear. In some vaccine studies, antibodies were found largely
dispensable [22], whereas studies of vaccines based on the major
outer membrane protein (MOMP) found the fine specificity of
the humoral response to be critically important [23]. Others
have suggested that serum antibodies do not operate through
neutralization and that protection against Ct requires CD4
+ T cell
subsets in collaboration with antibodies [21,24].
It has become clear that an effective subunit vaccine against Ct
must contain multiple epitopes to ensure broad coverage of a
genetically heterogeneous population infected with multiple
serovars of Ct (D to L). The strategy in our laboratory is therefore
focused on the molecular engineering of recombinant fusion
proteins containing several selected chlamydial vaccine antigens.
We have previously demonstrated that fusion proteins can induce
amplified responses to molecules with low inherent immunoge-
nicity, leading to significantly higher protection compared to single
components or mixtures [25]. The fusion protein approach offers
the advantage of a more defined product, reducing the number of
recombinant expression and purification steps required. This
reduces in turn, the cost of production compared to production
and mixing of multiple individual antigenic components.
The purpose of the current study was to evaluate the potential
of a subunit vaccine based on the fusion protein CTH1 consisting
of the two immunodominant antigens CT443 (omcB) and CT521
(rl16). These antigens were chosen because they represent targets
for both arms of the immune system. CT443 is a target for both
strong humoral and CMI responses [26] and CT521 was recently
discovered by our group to be a strong and frequent target for T
cells during natural Ct infection in humans [27]. Both of these
antigens are highly conserved (.97% homology) across the
different serotypes and can be expected to provide substantial
levels of cross protection. We examined the immunogenicity and
protective efficacy of this fusion protein in comparison to an
intranasal (i.n.) Chlamydia muridarum (MoPn) infection known to
provide a strong protective immune response in the mouse model.
CTH1 was combined with the liposomal adjuvant CAF01, known
to promote the induction of both CMI and humoral immune
responses [28,29]. Our data demonstrated that although this
subunit vaccine induced a high quality protective CD4
+ T cell
response and high levels of CTH1-specific antibodies in both
serum and the genital tract, it fails to provide complete protection.
Results
Experimental vaccine based on a recombinant fusion
protein between CT521 and CT443
A fusion protein of CT521 and CT443 (CTH1) was
recombinantly expressed in E. coli, affinity purified, subjected to
ion exchange chromatography, and analysed by sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) together
with the individual proteins CT521 and CT443 (Fig. 1A). Western
blotting demonstrated that CTH1 retained the ability to bind
antibodies against both components (Fig. 1B). The initial
immunological investigations were done to compare the immu-
nogenicity of the fusion protein with that of the single components
and to clarify whether both components of the fusion proteins
were recognized by the immune system after immunization.
Groups of C3H/HeN mice were immunized subcutaneously three
times at two weeks intervals with 5 mg of either the fusion protein
or the single components combined with CAF01, an adjuvant
known to promote the induction of a highly efficient Th1 and
antibody responses [28–30]. The immune response to the fusion
protein and the single components were investigated five weeks
after the last immunization. Immunization with 5 mg of the
fusion protein induced a strong IFN-c release in response to re-
stimulation with either the fusion protein or the homologous
proteins. Moreover the level of IFN-c release in response to both
CT443 and CT521 restimulation was enhanced in the CTH1
immunized group compared to immunization with the single
components (Fig. 2A). Neither mice receiving the adjuvant
combination alone (Fig. 2A) nor non-vaccinated naive mice
(results not shown) responded to restimulation with CTH1, CT443
and CT521. Six weeks after the last vaccination the mice were
challenged intravaginally (i.vag.) with 1610
7 inclusion forming
units (IFU) of Ct Serovar D. Vaginal swab samples were obtained
at day 3 and 7 and the protective effects of CTH1/CAF01,
expressed as median log10 IFU/mouse. Figure 2B shows the
Figure 1. SDS-PAGE and Immunoblotting. A. SDS-PAGE analysis of purified recombinant Ct serovar D antigens. 1–1.5 mg of protein was loaded
in each lane. Lane 1, CT521; Lane 2, CT443; Lane 3, CTH1; Lane 4, molecular weight standard. Protein bands were visualized by coomassie blue
staining. B. Western blot of CTH1 was performed with 1 mg of protein pr. lane. The nitrocellulose membrane was reacted with specific anti-CT521 and
anti-CT443 rabbit serum and anti-penta-His (Qiagen, Ballerup, Denmark) (Lane 2, 3 and 4 respectively).
doi:10.1371/journal.pone.0010768.g001
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infection. CT521/CAF01 did not significantly reduce the vaginal
bacterial shedding (P.0.05) whereas mice immunized with
CT443/CAF01 had significantly reduced bacterial shedding with
a median reduction of 0.9 log10 IFU/mouse (P,0.01). In
comparison mice vaccinated with CTH1/CAF01 reduced the
bacterial shedding with 1.46 log10 IFU/mouse (P,0.001)
compared to the control group (from 2.46 log10 to 1.0 log10). At
day 7 post infection there was no significant difference between
vaccinated and non-vaccinated mice (results not shown).
CTH1/CAF01 and MoPn infection induced a different
clearance kinetic
A Ct Serovar D infection is cleared fast in the mouse model
resulting in a narrow window for analysing the protective efficacy
of a vaccine. Since CT521 is 99% and CT443 97% homologous
between Ct serovar D and MoPn, we continued by investigating
the effect of this vaccine construct in the well established MoPn
mouse challenge model. Compared with the brief course of
infection with Ct serovar D, MoPn is significantly more virulent
than Ct serovar D and gives rise to a fully developed infection that
is cleared between 4–5 weeks post challenge and is associated with
disease related pathology [31,32]. This model therefore allows
more detailed studies of the dynamics and mechanisms involved in
the vaccine promoted protection and importantly allows a
comparison with a well established positive control (prior i.n.
infection with MoPn), that provides high levels of protection
against a genital challenge [33]. Two different mice strains
representing different haplotypes, C3H/HeN (H-2k) and CB6F1
(H-2b and H-2d) were immunized 3 times with 5 mg of CTH1/
CAF01 or rendered immune by prior i.n. infection. Six and 8
weeks post vaccination and i.n. infection, respectively, the mice
were challenged i.vag. with 1610
5 MoPn and vaginal swabs were
taken at different time points from day 3 to 35 after challenge
infection. Figure 3A and B shows the number of isolated bacteria
in the vaginal swabs expressed as median log10 IFU/mice in C3H/
HeN and CB6F1 mice, respectively. Compared to the control
group the CTH1/CAF01 immunized C3H/HeN mice displayed
significantly reduced vaginal bacterial shedding at day 7, 14 and
21 post infection (P,0.01) with the most efficient protection
expressed at day 14–21 (median IFU/mouse reduced by 1.1–1.9
log10) (Fig. 3A). The CTH1 based vaccine also significantly
protected CB6F1 mice ranging from 1.5–2.4 log10 reduction in
IFU’s (Fig. 3B). Mice immunized by prior i.n. infection with MoPn
cleared the challenge infection in a highly accelerated manner.
Whereas CTH1 vaccinated mice had a delay of one week before
the first manifestation of protection the i.n. infected group induced
a high level of protection immediately after challenge and already
at day 7–14 post infection these mice had resolved the infection.
CTH1/CAF01 subunit vaccination and MoPn infection
promotes a different distribution of cytokine producing
CD4
+ T cell subsets
Prophylactic vaccination with CTH1/CAF01 reduced the
number of bacteria significantly compared to the control group,
but with a lower level of protection and a delayed kinetic
compared to a prior i.n. MoPn infection. We therefore
characterized and compared the T cell and antibody responses
generated by the CTH1/CAF01 vaccine and the i.n. MoPn
infection. C3H/HeN mice were vaccinated three times with
CTH1/CAF01 or infected i.n. with 5000 IFU of MoPn. As control
we included a group of non-vaccinated mice. Five weeks after the
last vaccination or 7 weeks after the i.n. MoPn infection, the
spleens were isolated from 4 individual mice and splenocytes were
stimulated in vitro with the homologous antigen preparations,
CTH1 and MoPn EBs, respectively. Antigen-specific CD4
+ and
Figure 2. Vaccine-induced immune responses and protection against C. trachomatis serovar D. (A) Antigen specific responses by PBMC 5
weeks after the last immunization with CTH1 or the single components CT521 and CT443. C3H/HeN mice were immunized three times at 2 weeks
intervals with either CT521 or CT443 or CTH1 emulsified in CAF01. Cell cultures pooled from 13 animals in each group were re-stimulated with 5 mg/
ml of CT521, CT443, CTH1and a negative control well (C) without antigen and the IFN-c responses were measured after 72 h of stimulation. Each
point represents the mean of triplicate values6standard deviations. The experiment was performed twice with similar results. (B) Vaccine-induced
protection. Six weeks after the final vaccination mice were infected i.vag. with 1610
7 IFU of C. trachomatis Serovar D/mouse. Median vaginal bacterial
loads6interquartil ranges are compared for mice receiving CTH1 (n=8), CT443 (n=8), CT521 (n=8), and controls consisting of naı ¨ve and CAF01
immunized mice (n=16) at day 3 post infection. Culture-negative mice were assigned the lower cut-off of the shedding assay (10 IFU/mouse) **,
P,0.01; ***, P,0.001 compared to the control group (Kruskal-Wallis-test, Dunn’s posttest).
doi:10.1371/journal.pone.0010768.g002
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+ T cells were characterized based on their ability to secrete
the cytokines IFN-c, TNF-a and IL-2 at the single cell level by
intracellular FACS staining. The CD4
+ and CD8
+ T cells were
analyzed in terms of their CD44 expression and CD44
high T cells
were assessed for their cytokine-production to establish the
proportion of CD4
+ and CD8
+ cells positive for IFN-c, TNF-a
and IL-2 (Fig. 4A). The CD4
+CD44
high and the CD8
+CD44
high T
cell populations was separated into seven distinct sub-populations
based on their production of IFN-c, IL-2 or TNF-a in any
combination and the representation of each of these sub-
populations within the pool of T cells established (Fig. 4B). In
the CTH1 vaccinated group, multifunctional CTH1-specific
CD4
+ T cells expressing TNF-a/IL-2 (double positive) and IFN-
c/TNF-a/IL-2 (triple positive) CD4
+ T cells, which has been
associated with memory [34,35], constituted around 1/3 of the
total CTH1 specific CD4
+ T cell population. In comparison the
i.n. MoPn infection only induced a very low level of these CD4
+ T
cell subsets and was dominated by CD4
+ T cells producing IFN-c/
TNF-a (double positive) (Fig. 4C). Neither the vaccine nor the i.n.
infection induced detectable numbers of CTH1 and MoPn EB
specific CD8
+ T cells (Fig. 4C) and non-vaccinated mice did not
recognize the vaccine components (results not shown).
CTH1/CAF01 mediated protection is CD4
+ T cell
dependent in the MoPn model
We continued by investigating the contribution of the CD4
+ T
cells in the protective immune response promoted by CTH1/
CAF01 and i.n. MoPn infection. C3H/HeN mice were vaccinated
3 times with CTH1/CAF01 or infected once i.n. with 5000 IFU of
MoPn. A non-vaccinated group was included as control. At three
time points before challenge (Day -7, -5 and -3), 8 mice from each
group were depleted of CD4
+ T cells through injection of
monoclonal anti-mouse CD4 antibodies (GK 1.5). Injection of a
relevant rat IgG2b (isotype control) in a separate group had no
impact on the number of CD4
+ T cells (data not shown). Six weeks
after the last immunization with CTH1/CAF01 or 8 weeks after
the primary i.n. MoPn infection the mice were challenged i.vag.
with 10
5 MoPn and vaginal swabs were taken at day 3, 7, 14, and
21 post infection. The depletion of CD4
+ T cells was continued by
injections of GK.1.5 every 3–4 days (Day +1, +4, +8, +11, +15,
+18 and +22). FACS analysis on the blood 2 days after challenge
showed that the CD3
+/CD4
+ cell population of the total CD3
population was between 0–0.23% in mice receiving GK1.5
compared to approximately 60% in non-depleted mice, indicating
a very efficient depletion of the CD4
+ T cell subset in treated
animals (Fig. 5A) which was maintained throughout the infection
period. The absence of CD4
+ T cells was also seen in collagenase
treated genital tract tissue of depleted mice (Figure S1). In
agreement with this, CD4-depleted CTH1/CAF01 immunized
and i.n. MoPn infected mice only induced marginal IFN-c
responses to CTH1 or MoPn EBs, respectively compared to the
non-depleted mice (Fig. 5B) The CD4-depletion had no effect on
the level of specific antibody to neither CTH1 nor MoPn EB
(Fig. 5C). CTH1 immunization induced high levels of IgG1 and
IgG2a but no IgA, whereas the i.n MoPn infected mice induced
high levels of all three types. Analysis of the vaginal bacterial
shedding showed that the protection promoted by CTH1/CAF01
vaccination (Fig. 6A, top panel) was completely eliminated after
CD4
+ T cell depletion (Fig. 6B, top panel), suggesting that the
protection from CTH1/CAF01 vaccination is solely CD4
+ T cell
dependent. In agreement with earlier observations (Fig. 3A) mice
i.n. infected with MoPn reduced the level of bacterial shedding
with 4 log10 as early as day 3 post challenge infection (Fig. 6A,
lower panel). Depleting CD4
+ T cells in this group resulted in
impaired resistance and 1.5–3 log more bacteria throughout
infection demonstrating a clear involvement of CD4
+ T cells also
in the protection promoted by prior i.n. infection with MoPn
(Fig. 6B, lower panel). It was on the other hand clear that even in
the absence of CD4
+ T cells, bacterial shedding was reduced with
around 3 log10, compared to the non-immunized group which
suggests an effector mechanism independent of CD4
+ T cells in
the i.n. immunized group.
CTH1/CAF01 induced high levels of specific antibodies
but with limited binding potential for the chlamydial EBs
We finally compared the capacity of antibodies generated after
CTH1/CAF01 vaccination and i.n. MoPn infection to bind to the
MoPn EBs. Vaginal secretions from CTH1/CAF01 immunized,
i.n. MoPn infected, and control animals were tested by ELISA
coated with CTH1 and chlamydial EBs. We found that CTH1/
CAF01 immunization induced very high levels of CTH1-specific
IgG1 and IgG2a in the vaginal secretions (Fig. 7A, black bars).
However, these CTH1/CAF01 specific antibodies only had
minimal ability to bind MoPn EBs (Fig. 7B, black bars) or Ct
serovar D (results not shown). No CTH1 or MoPn EB specific IgA
could be detected after CTH1/CAF01 immunization. In contrast
i.n MoPn infection was associated with high levels of IgA in the
vaginal secretions directed to both CTH1 and MoPn EB (Fig. 7A
and 7B (gray bars)).
Discussion
T helper-type 1 (Th1)-type CMI responses play a predominant
role in anti-chlamydial protective immunity [12,13,36]. Identification
Figure 3. Vaccine-induced protection against MoPn. Mice were either vaccinated 3 times at 2-week intervals with CTH1/CAF01 or i.n infected
with 5610
3–1610
4 MoPn. Six and 8 weeks post last vaccination or infection, respectively mice were i.vag. infected with 1610
5 IFU of MoPn. Median
vaginal bacterial loads6interquartil ranges at different time points post infection are compared in C3H/HeN mice (A) or CB6F1 mice (B). Culture-
negative mice were assigned the lower cut-off of the shedding assay (10 IFU/mouse). * P,0.05, ** P,0.01; *** P,0.001 compared to the control
group (Kruskal-Wallis-test, Dunn’s posttest).
doi:10.1371/journal.pone.0010768.g003
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+ T cells [37–40] and delivery of these
antigens to induce a strong CMI response is therefore a central goal
when developing novel vaccines against Ct. In the present study we
have genetically engineered a fusion molecule encoding two
chlamydial proteins; CT521 that resides in the cytosol of reticulate
bodies during the replicating cycle (data not shown) and CT443
(omcB) located in the outer cell wall [41,42]. Both proteins are
frequently recognized by T cells from patients with a confirmed
genital chlamydial infection [26,27] and CT443 is, in addition, a well
known antibody target [26,43,44].
The CTH1 antigen was delivered in CAF01, an adjuvant system,
known to induce both strong CMI and antibody response [28–30].
Our study demonstrates that this vaccine promotes significant
protection against genital infection in mice infected with either Ct
serovar D or MoPn. Ct serovar D has relatively low virulence in the
mouse and gives rise to a transient infection. The protection
promoted by the vaccine was therefore evident at day 3 post
infection, but by day 7 the window between vaccinated and control
animals became too narrow to detect any significant difference.
Since the Ct Serovar D sequence of the CTH1 protein is 97%
homologous to the MoPn sequence of CTH1 we decided to
investigate the protective capacity of CTH1 using MoPn as
challenge strain. Compared to the Ct serovar D challenge model
we found the kinetic of bacterial growth and elimination to be
different. There was no initial reduction in IFU in vaccinated
animals, but from day 14–21 we could detect up to a 2 fold
reduction in IFUs compared to a control group. The level of
protection and the delayed clearance was not due to a lack of strain
specific immunity as later experiments have demonstrated similar
infection dynamics after vaccination with a MoPn version of CTH1
(results not shown). Importantly, the CTH1 mediated reduction of
IFU was found to be mediated exclusively by CD4
+ T cells.
CMI-induced protection has been observed in other recent
studies promoted by subunit vaccines based on CPAF or NrdB in
Figure 4. IcFACS analysis of cytokine expression in CD4
+ and CD8
+ T cells after CTH1/CAF01 immunization and i.n. MoPn infection.
(A) Gating tree for phenotypic and functional characterization of CD4
+ T cells in CTH1/CAF01 immunised mice by multiparameter flow cytometry.
Splenic cells were analysed at 5 weeks after last vaccination or 7 weeks post i.n. MoPn infection by icFACS based on individual spleen cells (4 mice/
group) stimulated with either CTH1 or MoPn-EBs. Lymphocytes were gated based on their FSC vs. SSC profile, and the CD4
+CD44
high T cell population
was further subdivided into various cytokine-producing subsets. (B) Cytokine-producing cells (IFN-c, TNF-a, IL-2) within the CD4
+CD44
high population
were divided into seven distinct subpopulations based on their production of these cytokines in any combination. (C) Bar chart shows the frequency
of each subset within the CD44
high CD4
+ and CD8
+ T cell populations. The experiment was repeated twice with similar results.
doi:10.1371/journal.pone.0010768.g004
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adjuvants, respectively. For both of these vaccines, protection was
found to be dependent upon CD4
+ T cells producing IFN-c
[38,45,46]. IFN-c has often been used as a single readout for Th1
responses, but recent studies of other infectious diseases have
emphasized the importance of polyfunctional T cells co-producing
IL-2, IFN-c and TNF-a [14,47]. Here we demonstrated that
CTH1/CAF01 immunized animals had a high percentage of
antigen specific CD4
+ T cells co-expressing IFN-c/TNF-a/IL-2
or TNF-a/IL-2. IL-2 co-expression has been demonstrated to play
an important role in the long-term survival of primed CD4
+ T cells
in vivo [34,35]. Furthermore these polyfunctional cells have been
demonstrated to correlate with efficient protection against other
intracellular pathogens such as Leishmania major and Mycobacterium
tuberculosis [14,48]. In the present study, the proportion of
polyfunctional T cells are much higher in the CTH1/CAF01
immunized group compared to the i.n. MoPn infected group. This
suggests that the CTH1 vaccine promotes a fully-adequate, high
quality T cell response, as do other vaccines employing the
liposome based adjuvant CAF01 [48]. It is therefore likely that
the explanation for the lower levels of protection promoted by the
subunit vaccine should be sought elsewhere than in the quality of
the CMI response induced. In agreement with this, our data
clearly demonstrate that whereas the protection in the subunit
Figure 5. Immune responses of CD4-depleted and non-depleted mice. (A) The density plot represents CD4
+ and CD8
+ T cells in PBMCs 2
days post challenge in non-depleted (top panel) and CD4-depleted mice (lower panel). (B) CTH1-specific and MoPn-specific IFN-c responses in
depleted and non-depleted CTH1 vaccinated and i.n. MoPn infected C3H/HeN mice. The IFN-c responses were measured in triplicate cell cultures
pooled from 3 animals/group 2 days post challenge. Each group was re-stimulated with 5 mg/ml of CTH1 and HIA-MoPn and IFN-c responses were
measured after 72 h of stimulation. Each bar represents the mean of triplicate values6standard deviations, (C) CTH1-specific and MoPn-specific
antibodies generated after CTH1 vaccination or i.n. MoPn infection in CD4 depleted and non-depleted mice Antibodies (IgG1, IgG2a and IgA) were
measured in serum (diluted 5 fold from a 1:20 dilution) obtained 2 days after challenge infection, by ELISA. Reciprocal serum dilutions corresponding
to 50% maximal binding (EC50) were computed using the Prism 4 software. Each bar represents the mean EC506SEM of 3 individual mice. The
experiment was repeated twice with similar results.
doi:10.1371/journal.pone.0010768.g005
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+ T cells, the i.n.
MoPn infected mice displayed a very substantial protective
immune response even in the absence of CD4
+ T cells.
The CD4
+ T cell independent effect is most likely not mediated
by CD8
+ T cells as CD8-depletion of i.n. infected mice had
minimal influence on the level of protection (authors’ unpublished
observations). This is in agreement with other observations from
mouse models of genital tract infection where immunity is neither
diminished in the absence of CD8
+ T cells nor is any significant
protection conferred by CD8
+ T cells [12,49,50]. Another T cell
subset that has been demonstrated to play a potential role in the
immune response to intracellular pathogens is cd T cells. Similarly
to CD4
+ and CD8
+ T cells, cd T cells secrete IFN-c, can lyse
infected macrophages and can help contain bacterial growth
(reviewed in [51]). Their role in Chlamydia infection, although still
not completely resolved, seems to be very modest [13,52] and is
therefore most likely not responsible for the CD4 independent
protection we observe in the present study. However, a number of
important studies from Morrison and colleagues have indicated a
previously unrecognized protective role for antibodies and B cells
against secondary genital chlamydial infection in mice
[20,21,50,53]. The mechanisms of action for antibodies in
immunity to Chlamydia remain unresolved and data from
different laboratories collectively suggest a more complex role
than just direct neutralisation of the invading pathogen. Mice
deficient in activating Fc receptors (FcR2/2 mice) had impaired
resistance to secondary chlamydial challenge [24,54]. This has
been interpreted to suggest that the effects of antibody may occur
via Fc receptor-dependent mechanisms that could accelerate the
subsequent CMI response. That CMI and antibodies interact in
protection against Chlamydia was also emphasized by the finding
that antibody-mediated protection is highly dependent on CD4
+ T
cell-mediated adaptive changes that occur in the local genital tract
tissues during primary infection [53]. Our study demonstrates that
CTH1/CAF01 vaccination induced high levels of CTH1 specific
IgG1 and IgG2a both in blood and vaginal secretions. However,
the antibodies were only weakly reactive to chlamydial EBs of
either MoPn (Fig. 7) or Ct serovar D. In contrast, mice i.n infected
with MoPn induced high levels of IgA directed to EBs in both
serum and vaginal wash. There are at least two explanations for
this difference. It may relate to the recognition of multiple target
antigens on the surface of EB in the i.n. vaccinated group as
demonstrated elsewhere [55], compared to the focused response in
CTH1 vaccinated animals directed to CT443 and CT521. The
weak binding of CTH1-specific antibodies to the whole EB
preparation could be explained by a relatively low concentration
of CT443 and CT521 in the ELISA wells of EB coated plates
compared to CTH1 coated plates. Alternatively, the weak
recognition of the EB preparation in the CTH1 vaccinated mice
may relate to differences in the conformation of the two vaccine
antigens in their natural localization in EB’s compared to the
recombinant vaccine construct. CT443 (OmcB) was originally
identified as part of the outer membrane complex [41], and recent
data have demonstrated that this molecule functions as a
chlamydial adhesin [42], emphasizing its surface localization.
CT443 may however suffer from the same problem as MOMP,
where a number of recent studies have demonstrated that the
optimal antibody response and protective efficacy depends on its
native conformation-something that has so far not been possible to
achieve with recombinantly expressed MOMP [23,56].
Figure 6. Importance of CD4
+ T cell immunity in vaccine-mediated protection. C3H/HeN mice depleted of CD4
+ T cells received i.p.
injections of 250 mg of anti–mouse CD4 monoclonal antibody (clone GK1.5) on days -7, -4, -3 and of 400 mg purified antibody at day +1, +4, +8, +11,
+15,+18,+22 relative to the day of infection. Mice were vaccinated and challenged as described for Fig. 2. Swab samples were obtained on days 3, 7,
14, 21 and 35 post infection. Median vaginal MoPn loads6interquartile ranges were compared for (A), top panel: control mice (n=20) vs. CTH1/
CAF01 vaccinated mice (n=16). (A), lower panel: control mice (n=20) vs. i.n. MoPn infected mice (n=8) (B), top panel CD4-depleted control mice
(n=8) vs. CD4-depletion CTH1/CAF01 immunized mice (n=8). (B), lower panel: CD4-depleted control mice (n=8) vs. CD4-depleted i.n. MoPn infected
mice (n=8). Culture-negative mice were assigned the lower cut-off of the shedding assay (10 IFU/mouse). **, P,0.01; *** P,0.001 compared to the
control group (Kruskal-Wallis-test, Dunn’s post test).
doi:10.1371/journal.pone.0010768.g006
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promoted by i.n. infection is mediated partly by a CD4
independent mechanism. Our CTH1 construct efficiently induces
both CD4 T cell and a surface targeted antibody response. While
the CTH1 vaccine obviously needs further improvement this will
not necessarily be achieved by the incorporation of additional
antigens. CTH1 may face the same hurdles as often encountered
in attempts to recombinantly produce biologically active proteins,
where refolding into bioactive forms is cumbersome, results in
poor recovery and accounts for the major cost and complexity. For
a fusion molecule like CTH1 which incorporates the cysteine rich
CT443, restoration of the native-like secondary structure or at
least exposure of important linear B cell epitopes will obviously be
very difficult and demand carefully targeted mutagenesis of
selected cysteine residues. Work towards this goal is currently
ongoing in our laboratory.
Materials and Methods
Ethics Statement
The handling of mice was conducted in accordance with the
regulations set forward by the Danish Ministry of Justice and
animal protection committees by Danish Animal Experiments
Inspectorate, and in compliance with European Community
Directive 86/609 and the U.S. Association for Laboratory Animal
Care recommendations for the care and use of laboratory animals.
All the techniques/procedures have been refined to provide for
maximum comfort/minimal stress to the animals.
Organisms
The C. muridarum strain MoPn/NiggII and C. trachomatis serovar
D was purchased from the ATCC and propagated in HeLa-229
cells as described previously [27]. Chlamydial EBs were harvested,
purified and quantified as described previously [27,30] and stored
at 280uC in a 0.2 M sucrose, 20 mM sodium phosphate and
5 mM glutamic acid buffer (SPG).
Cloning, gene expression and protein purification of
recombinant proteins for vaccination
Cloning of vaccine hybrid construct CTH1. DNA frag-
ments containing the genes of ct521 and ct433 were amplified from
Ct serovar D genomic DNA by overlap extension PCR [57].
Amplifications were carried out for 25 cycles each with
denaturation at 94uC for 30 sec, annealing at 55uC for 30 sec,
and extension at 72uC for 2 min, using Phusion polymerase
(Finnzymes, Espoo, Finland). Nucleotide sequencing was
performed directly on the PCR products by MWG-Biotech AG
(Germany) using specific sequencing primers. The ct521-ct433
gene fusion was created using the specific primer Ct521_fw_1 (59-
CAC CGG ATC CAT GTT AAT GCC TAA ACG AAC AAA
ATT TC and Ct521_rev_1 (59- CAC CCC GCT AGC AAA
TAA ACT TAC CCT TTC CAC ACG CTT AAC AAA) [ct521],
Ct443_fw_1 (59-TTT GTT AAG CGT GTG GAA AGG GTA
AGT TTA TTT GCT AGC GGG GTG) and Ct443_rev_1 59-
GGA TCC CTA ATA GAT GTG TGT ATT CTC TGT ATC
AGA AAC TG [ct433] in a first round PCR using chlamydial
DNA extracted as described in [58] as the template. The
respective products were used as templates in second round
PCR using the primers Ct521_fw_1 and Ct443_rev_1. The
resulting DNA fragment was cloned into pENTR/D-TOPO and
subsequently into pDEST17 expression vector (Invitrogen,
Copenhagen, Denmark) thereby creating an in frame fusion
with 6*His tag.
Recombinant gene expression and protein purifi-
cation. Escheria coli BL-21 AI cells transformed with plasmid
pDEST17 (Invitrogen, Copenhagen, Denmark) encoding CTH1
were grown at 37uC to reach the logarithmic phase OD600 ,0.5
and protein expression was induced by adding arabinose to total
concentration of 0.2%. The protein expression was induced for
4 hours and cells were harvested by centrifugation (6,000 g for
15 min.). E. coli were lysed using Bugbuster (Novagen, Darmstadt,
Germany) containing Benzonase, rLysozyme and Protease
inhibitor Cocktail I (Calbiochem, San Diego, CA) to avoid
unwanted degradation. Lysis was performed at room temperature
for 30 min. during gentle agitation. Inclusion bodies were isolated
by centrifugation (10,000 g for 10 min.) The pellet was washed
once with 1:5 diluted Bugbuster solution in 3 M urea and then
dissolved in 50 mM NaH2PO4, 0.4 M NaCl, 8 M Urea, 10%
glycerol, 10 mM Imidazole pH 7.5. This solution was loaded onto
a 5 ml HisTrap HP (Amersham Biosciences, Buckinghamshire,
United Kingdom) and the bound proteins were eluted by applying
a gradient of 50 to 500 mM imidazole. Fractions containing the
desired recombinant protein were pooled, dialyzed against 20 mM
ethanolamine, pH 9, 8 M urea and applied to a 5 ml HiTrap Q
Sepharose HP (Amersham Biosciences, Buckinghamshire, United
Kingdom). The recombinant protein was eluted by applying a
gradient of 0 to 1 M NaCl over 10 column volumes. Analysis of all
fractions was performed by SDS-PAGE. Protein concentrations
were measured by the BCA protein assay (Pierce, Rockford,
Figure 7. CTH1-specific (A) and MoPn-specific (B) antibodies
generated after vaccination or i.n MoPn infection. Mice were
either immunized with CTH1/CAF01 or infected i.n. with MoPn. Non-
immunized control mice were included as controls. Antibodies (IgG1,
IgG2a and IgA) were measured in vaginal secretions (dilution shown
1:10) obtained 8 days after challenge infection, by ELISA. Each symbol
and bar represents the mean Abs 4506SD of 4 individual mice.
doi:10.1371/journal.pone.0010768.g007
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coomassie staining and western blot with anti-penta-His (Qiagen,
Ballerup, Denmark) and anti-E. coli antibodies to detect
contaminants (DAKO, Glostrup, Denmark). CTH1 was refolded
by a stepwise removal of buffer containing urea ending up in
20 mM Citrate-phosphate buffer pH 4, 10% glycerol, 1 mM
cysteine which yielded soluble protein.
Recombinant gene expression and protein purification of
CT443 and CT521 was done as described in [26]. The purified
recombinant proteins were stored at 220uC until use.
SDS-page and Immunoblotting
SDS-PAGE and western blot of CT521, CT443 and CTH1 was
performed with 1 mg of protein pr. lane (Figure 1 A and B). The
nitrocellulose membrane was reacted with specific anti-CT521,
anti-CT443 rabbit serum and anti-penta-His (Qiagen, Ballerup,
Denmark) (Lane 2, 3 and 4 respectively).
Immunizations
Female 6–8 weeks old C3H/HeN and CB6F1 mice were
purchased from Harlan Scandinavia (Denmark). Animals were
immunized subcutaneously with 1–5 mg/dose of CT521, CT443
or CTH1 in 100 ml sterile Tris-buffer (pH 7.4) mixed by vortexing
with 100 ml CAF01 adjuvant (SSI) consisting of 50 mg/dose of the
glycolipid trehalose 6,69-dibehenate (TDB) incorporated into
250 mg/dose of cationic liposomes composed of dimethyldiocta-
decylammonium (DDA) bromide [28]. Mice received a total of
three immunizations at two week intervals. Ten and 3 days before
MoPn or Ct serovar D challenge, the oestrus cycle was
synchronized by injection of 2.5 mg Medroxyprogesteronacetat
(Depo-Provera; Pfizer). Six weeks after the final vaccination the
mice were challenged i.vag. with 1610
5 IFU of MoPn or 1610
7
IFU of Ct serovar D in 10 ml SPG buffer. For i.n. infection with
MoPn, mice received from 5610
3 to 1610
4 bacteria 8 weeks prior
to i.vag. challenge. Specific antisera against CT443 and CT521
were generated by injecting recombinant proteins 50 mg into
rabbits in combination with Montanide ISA720. Two booster
doses were administered at 2-week intervals.
Depletion of CD4
+ T-cells
Monoclonal anti-mouse CD4 IgG2b (clone GK1.5) was purified
from hybridoma supernatants made in our lab, using HiTrap
protein G HP columns (Amersham Biosciences). The purified IgG
was dialyzed against PBS, sterile filtered and the protein
concentration was determined. Mice were depleted of CD4
+ T-
cells by the i.p route with 3 injections of 250 mg purified antibody
each at day -7, -5, -3 followed by 400 mg purified antibody at day
+1, +4, +8,+11,+15,+18,+22 relative to the day of infection. The
depletion of CD4
+ T-cells was verified by FACS analysis on
PBMCs at day, +2, +7, and day +16 relative to the day of infection
using a FITC conjugated anti-CD4 antibody (clone RM4-4), a PE
conjugated anti-CD8 antibody (clone 53-6.7) and a APC
conjugated anti-CD3 (clone 145-2C11)(BD Biosciences). Likewise,
genital tract tissue was removed collagenase (0.7 mg/ml)/DNAse
(40 mg/ml) treated for 1 h and surface stained for FACS analysis.
Injection of isotype control antibody was found to have no impact
on the size of the CD4
+ T-cell population.
Measurement of antibody levels in serum and vaginal
secretions
Blood and vaginal secretion fluid were collected for quantifica-
tion of vaccine-specific antibodies by ELISA. Blood were collected
from the periorbital vein plexus and centrifuged 2500 c.p.m. to
separate serum. Vaginal secretion samples were collected by
flushing the vagina with 100 ml of sterile PBS. Maxisorb Plates
(Nunc, Roskilde, Denmark) were coated with either CTH1 (1 mg/
ml) or heat inactivated (HIA) MoPn EBs (10 mg/ml) and the
samples were serially diluted before added to ELISA-plates. Serum
samples and vaginal secretion fluid were 5 fold diluted 8 times
from a 1:20 and 1:10 dilution, respectively. Antigen-specific IgG1,
IgG2a, and IgA were detected with isotype-specific HRP-
conjugated rabbit anti-mouse IgG (Zymed) diluted 1:5000.
Substrate was TMB-PLUS (Kem-En-TEC, Taastrup, Denmark).
Reciprocal serum dilutions corresponding to 50% maximal
binding (EC50) were computed using the GraphPad Prism 4.
Chlamydia-specific cellular responses
Blood lymphocytes were purified on a density gradient. Cells
were pooled from 3–13 mice in each group. Single-cell suspensions
were prepared from individual spleens (4 mice/group) and
obtained by homogenisation through a metal mesh and washed
twice in RPMI-1640 (Gibco Invitrogen, Taastrup, Denmark). All
cell cultures were grown in Nucleon microtiter plates (Nunc,
Roskilde, Denmark) containing 2610
5 cells/well in 200 ml RPMI-
1640 supplemented with 5610
25 M 2-mercaptoethanol, 1 mM
glutamine, 1% pyruvate, 1% penicillin-streptomycin, 1% HEPES
and 10% fetal calf serum (FCS) (Invitrogen, Taastrup, Denmark).
The cells were restimulated with either HIA-MoPn (5 mg/ml),
CTH1 (5 mg/ml), CT443 (5 mg/ml) or CT521 (5 mg/ml).
Stimulation with Concavalin A (5 mg/ml) (results not shown) or
media (C) were done as positive control for cell viability and
negative control, respectively. After 72 h of incubation at 37uC/
5% CO2, supernatants were harvested and stored at 220uC
before use. The amounts of secreted IFN-c were determined by
enzyme-linked immunosorbant assay (ELISA) as described
elsewhere [59].
Intracellular cytokine staining procedure
Splenocytes were stimulated over night with 5 mg/ml of CTH1
or HIA-MoPn at 37uC/5% CO2 and subsequently incubated for
5 h at 37uC with 10 mg/ml brefeldin A (Sigma-Aldrich, USA) and
0.7 ml/ml monensin/GolgiStop (BD Pharmingen). The cells were
washed in FACS buffer (PBS containing 0.1% sodium azide and
1% FCS) before surface staining with rat anti-mouse antibodies.
The intracellular cytokine staining procedure was done essentially
as described in [48]. Cells were washed with FACS buffer before
fixation and permeabilization using the BD Cytofix/Cytoperm
TM
(BD, San Diego, CA, USA). The following antibodies were used
for surface staining: PerCP-Cy.5.5-anti-CD8a (53-6.7), APC-Cy7-
anti-CD4 (GK1.5), and FITC-anti-CD44. The following antibod-
ies were used for intracellular staining: PE-anti-TNF-a, APC-anti-
IL-2, PE-Cy7-anti-IFN-c. All antibodies were purchased from BD
Pharmingen (San Diego, USA) or eBiosciences (San Diego, USA).
Vaginal chlamydial load
Vaginal swabs were obtained at 3, 7, 14, 21, 28 and 35 days
after infection. Swabs were vortexed with glass-beads in 1 ml SPG
buffer and stored at 280uC until analysis. Infectious load was
determined as described in [30]. Briefly, McCoy cell monolayers
were infected with a titrated volume of the swab suspension. The
plates were centrifuged at 7506g for 1 h at RT followed by
incubation at 35uC for 2 h. Infection-media was then replaced
with fresh media and the cells incubated at 37uC for 30 h.
Inclusions were visualised by staining with polyclonal rabbit anti-
MOMP serum made in our laboratory, followed by a FITC
conjugated swine anti-rabbit Ig (DAKO, Glostrup, Denmark).
Background staining was done with propidium iodide (Invitrogen,
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microscopy observing at least 20 individual fields of vision for each
well.
Statistical analysis
Statistical analysis was done using GraphPad Prism 4. Medians
of vaginal chlamydial load were analyzed using Kruskall-Wallis
followed by Dunn’s post test. A value of P,0.05 was considered
statistically significant.
Supporting Information
Figure S1 Genital tract tissue (representative of 4 individually
mice) was isolated from CD4- depleted and non-depleted i.n
MoPn infected mice and surface stained using a FITC conjugated
anti-CD4 antibody (clone RM4-4), a PE conjugated anti-CD8
antibody (clone 53-6.7) and a APC conjugated anti-CD3 (clone
145-2C11) antibody.
Found at: doi:10.1371/journal.pone.0010768.s001 (0.04 MB TIF)
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